Nuclear factor *κ*B (NF-*κ*B) is a critical regulator of multiple genes that control immunity, differentiation and other stress-induced responses.^[@bib1],\ [@bib2],\ [@bib3]^ In resting cells, NF-*κ*B is retarded in the cytoplasm by interacting with the inhibitor of *κ*B (I*κ*B) that blocks the nuclear localization signal of NF-*κ*B. In the canonical NF-*κ*B signaling pathway, stimuli such as tumor necrosis factor *α* (TNF*α*) recognition by the TNF receptor leads to activation of the inhibitor of I*κ*B*α* kinase (IKK). IKK then phosphorylates I*κ*B*α*, which results in K48-linked polyubiquitination of I*κ*B*α* followed by proteasome-dependent degradation.^[@bib4],\ [@bib5],\ [@bib6]^ NF-*κ*B dimers are then released and translocated into the nucleus, where they bind to specific DNA sequences and initiate transcription.^[@bib7]^

The activity of NF-*κ*B is strictly modulated at multiple levels by variant proteins, and protein modification by ubiquitin has a key regulatory function.^[@bib8],\ [@bib9]^ In addition to targeting I*κ*B*α* for degradation followed by NF-*κ*B precursor processing, ubiquitin has a critical role in activating IKK in a proteasome-independent manner.^[@bib10],\ [@bib11],\ [@bib12],\ [@bib13]^ Initially, it was found that IKK can be activated by ubiquitination without proteasomal degradation *in vitro*.^[@bib14]^ Soon after, a series of E3 ligases, which are now known as TNF receptor associate factors (TRAFs), were identified as key regulators of IKK by forming K63-linked ubiquitin chains on targeted proteins.^[@bib15],\ [@bib16],\ [@bib17]^ In the TNF*α*-activated NF-*κ*B pathway, TRAF2/5 catalyzes K63-linked ubiquitination of receptor-interacting protein 1 (RIP1) and subsequently promotes the interaction between RIP1 and NEMO.^[@bib18],\ [@bib19]^ The IKK complex is composed of three subunits: IKK*α*, IKK*β* and the regulatory subunit NF-kappa-B essential modulator (NEMO, also known as IKK-*γ*). NEMO has a ubiquitin-binding domain that binds to polyubiquitin chains to form a huge complex that facilitates the interaction between IKK*β* and its kinase TGF-*β*-activated kinase 1.^[@bib18],\ [@bib19]^ B-cell lymphoma/leukemia 10 and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) are also reported to activate NF-*κ*B by inducing K63-linked ubiquitin conjugation to NEMO.^[@bib20],\ [@bib21]^

Several strategies have been used by cells to downregulate NF-*κ*B and prevent persistent activation of NF-*κ*B. For example, dephosphorylation of IKK*β* by protein phosphatase 1, 2A or 2C*β* decreases IKK*β* activity.^[@bib22],\ [@bib23],\ [@bib24]^ Deubiquitinases (DUBs) have been reported to suppress NF-*κ*B activation by removing ubiquitin chains.^[@bib25],\ [@bib26],\ [@bib27]^ Among them, A20 and cylindromatosis (CYLD) are the most studied DUBs that negatively regulate NF-*κ*B activation. As a target gene of NF-*κ*B, A20 terminates NF-*κ*B signaling in a negative feedback loop. NF-*κ*B is persistently activated by TNF*α* and interleukin 1 (IL-1) in A20-deficient cells, and mice lacking A20 die prematurely owing to severe inflammation and cachexia.^[@bib28],\ [@bib29]^ CYLD is also an important negative regulator by preventing spontaneous activation of NF-*κ*B. NF-*κ*B is constitutively activated in the absence of CYLD.^[@bib30],\ [@bib31]^

HSCARG (also named NmrA-like family domain containing protein 1) is a newly identified NF-*κ*B suppressor. In our previous study, we found that HSCARG inhibits TNF*α*- and IL-1-activated NF-*κ*B by interacting with IKK*β* and suppressing its phosphorylation,^[@bib32]^ but the detailed molecular mechanism remain to be elucidated. In this study, we show that HSCARG interacts with NEMO and suppresses polyubiquitination of NEMO. Further investigation demonstrate that HSCARG and ubiquitin-specific protease 7 (USP7; HAUSP) function together to inhibit NEMO polyubiquitination, and USP7 suppresses TNF*α*-induced NF-*κ*B activation. In summary, our study uncovers the suppressive mechanisms of HSCARG and USP7 in the TNF*α*-activated NF-*κ*B signaling pathway.

Results
=======

HSCARG suppresses TNF*α*-stimulated NF-*κ*B signaling. Our previous study shows that HSCARG inhibits NF-*κ*B activity. To further confirm the inhibition of NF-*κ*B signaling by HSCARG under physiological conditions, the Cre/loxP system was used to generate *HSCARG*^*−/−*^ HCT116 cell line by inserting an extra sequence into the fourth exon and adding further stop codons to disrupt the translation of HSCARG. Knockout of HSCARG was confirmed by PCR ([Supplementary Figure S1a](#sup1){ref-type="supplementary-material"}) and western blotting analyses ([Figure 1a](#fig1){ref-type="fig"}, left panel). And then the NF-*κ*B activity of *HSCARG*^*−/−*^ cells was analyzed. Upon TNF*α* treatment, I*κ*B*α* degradation was faster in *HSCARG*^*−/−*^ cells compared with that in wild-type HCT116 cells with normal HSCARG ([Figure 1b](#fig1){ref-type="fig"}, right panel). Knockout of HSCARG also retarded the *de novo* synthesis of I*κ*B*α* ([Figure 1b](#fig1){ref-type="fig"}). We generated a stable human embryo kidney (HEK) 293T cell line expressing HSCARG ([Figure 1a](#fig1){ref-type="fig"}, right panel) and examined both the endogenously and ectopically expressed HSCARG ([Supplementary Figure S1b](#sup1){ref-type="supplementary-material"}). We found that I*κ*B*α* was accumulated more in stable HSCARG cells under resting state than that in HEK 293T cells. Consistently, a much higher level of I*κ*B*α* was detected in stable HSCARG cells followed by TNF*α* treatment ([Figure 1b](#fig1){ref-type="fig"}, lower panel).

We also found that knockout of HSCARG affected the subcellular translocation of NF-*κ*B. *HSCARG*^*−/−*^ cells were treated with TNF*α*, and then localization of p65 in the nucleus and cytoplasm was examined by western blotting analysis. The result showed that a higher amount of p65 translocated from the cytoplasm into the nucleus in *HSCARG*^*−/−*^ cells when compared with that in control cells ([Figure 1c](#fig1){ref-type="fig"}). The observations that TNF*α*-stimulated NF-*κ*B activaty increased significantly in *HSCARG*^*−/−*^ cells demonstrate that HSCARG is a strong inhibitor in the NF-*κ*B signaling pathway under physiological conditions.

HSCARG interacts with NEMO and inhibits its polyubiquitination. Identification of HSCARG as a strong inhibitor of NF-*κ*B activity encouraged us to elucidate the detailed molecular mechanism. Both ectopic and endogenous co-immunoprecipitation (co-IP) analysis showed that HSCARG interacted with NEMO ([Figure 2a](#fig2){ref-type="fig"}, left and middle panels, [Supplementary Figure S3a](#sup1){ref-type="supplementary-material"}), and TNF*α* treatment promoted this interaction ([Figure 2a](#fig2){ref-type="fig"}, right panel). Because NEMO can be modified by K63-linked ubiquitin chains, which is a key event for its interaction with upper intermediates and signal transduction, we next investigated whether HSCARG affected NEMO polyubiquitination. His-ubiquitin pull-down analysis showed that, in HEK 293T cells, endogenous NEMO was strongly detected with conjugated ubiquitin chains ([Figure 2b](#fig2){ref-type="fig"}, [Supplementary Figure S3b](#sup1){ref-type="supplementary-material"}). When HSCARG was overexpressed, polyubiquitin-conjugated NEMO decreased obviously, indicating that HSCARG strongly suppresses polyubiquitination of NEMO ([Figure 2b](#fig2){ref-type="fig"}). To further confirm the physiological function of HSCARG, we analyzed the variation of endogenous ubiquitinated NEMO after TNF*α* treatment. The results showed that TNF*α* treatment promoted NEMO ubiquitination, which was suppressed by ectopic expression of HSCARG ([Figure 2c](#fig2){ref-type="fig"}, [Supplementary Figure S3b](#sup1){ref-type="supplementary-material"}). On the contrary, knockout of HSCARG obviously increased the level of endogenous NEMO ubiquitination ([Figure 2d](#fig2){ref-type="fig"}, [Supplementary Figure S3b](#sup1){ref-type="supplementary-material"}). Altogether, these results indicate that HSCARG interacts with the regulatory subunit NEMO of the IKK complex and inhibits NEMO ubiquitin modification.

HSCARG interacts with USP7 and inhibition of NEMO polyubiquitination by HSCARG relies on the deubiquitination activity of USP7. As described above, HSCARG interacted with NEMO and inhibited its polyubiquitination. Because protein polyubiquitination has a key role in activation, regulation and termination of the NF-*κ*B pathway, and HSCARG is not a DUB, it is conceivable that HSCARG suppresses NF-*κ*B by interacting with some DUBs that can regulate polyubiquitin conjugation of NEMO. Several DUBs, including A20, CYLD and USP7, have been reported to downregulate NF-*κ*B. Co-IP assays were thus carried out to examine the interactions between these enzymes and HSCARG, and the results showed that HSCARG interacts weakly with A20 or CYLD but strongly interacts with USP7 ([Figure 3a](#fig3){ref-type="fig"}, [Supplementary Figure S3c](#sup1){ref-type="supplementary-material"}). Furthermore, the interaction between endogenous HSCARG and USP7 in cells treated with or without TNF*α* was investigated by co-IP assay. As expected, endogenous USP7 interacted with HSCARG, which was promoted by TNF*α* treatment ([Figure 3b](#fig3){ref-type="fig"}, [Supplementary Figure S3d](#sup1){ref-type="supplementary-material"}). Next, we examined whether knockdown of NEMO by siRNA affects the interaction between HSCARG and USP7. The result showed that knockdown of NEMO suppressed the binding between HSCARG and USP7, indicating an essential role of NEMO in regulating the interaction between HSCARG and USP7 ([Figure 3c](#fig3){ref-type="fig"}, [Supplementary Figure S3e](#sup1){ref-type="supplementary-material"}). We next investigated whether inhibition of NEMO polyubiquitination by HSCARG depended on USP7. In HEK 293T cells with depleted USP7 by shRNA, inhibition of NEMO polyubiquitination by HSCARG was attenuated obviously ([Figure 3d](#fig3){ref-type="fig"}, [Supplementary Figure S3f](#sup1){ref-type="supplementary-material"}). These results indicate that inhibition of NEMO ubiquitination by HSCARG relies on the deubiquitination activity of USP7.

USP7 interacts with NEMO and inhibits its polyubiquitination, and HSCARG is critical for the deubiquitination activity of USP7. We further examined whether USP7 interacted with NEMO and affected the level of NEMO polyubiquitination. USP7 and NEMO were co-transfected into HEK 293T cells, and co-IP experiment was carried out to analyze the interaction between these two proteins. We found that USP7 was immunoprecipitated with NEMO ([Figure 4a](#fig4){ref-type="fig"}, [Supplementary Figure S3g](#sup1){ref-type="supplementary-material"}). Moreover, an expression vector encoding Flag-NEMO was co-transfected with USP7 and HA-HSCARG into HEK293T cells or *HSCARG*^*−/−*^ HEK293T cells, and then the interaction among these three proteins was examined by co-IP analysis. The results showed that USP7, HSCARG and NEMO were immunoprecipitated together ([Figure 4b](#fig4){ref-type="fig"} left panel, [Supplementary Figure S3h](#sup1){ref-type="supplementary-material"}), and knockout of HSCARG impaired the binding between NEMO and USP7 ([Figure 4b](#fig4){ref-type="fig"} middle panel, [Supplementary Figure S3h](#sup1){ref-type="supplementary-material"}), indicating that these three proteins form a complex. This was confirmed by the endogenous co-IP experiments as shown in [Figure 4b](#fig4){ref-type="fig"} (right panel, [Supplementary Figure S3h](#sup1){ref-type="supplementary-material"}), in which TNF*α* treatment promoted the complex formation. To determine whether USP7 deubiquitinated NEMO polyubiquitination, we examined and compared the levels of NEMO polyubiquitination in HEK 293T cells with or without ectopic USP7. As expected, the results of ubiquitin conjugation assays showed that overexpression of USP7 strongly inhibited polyubiquitination of NEMO ([Figure 4c](#fig4){ref-type="fig"}, [Supplementary Figure S3i](#sup1){ref-type="supplementary-material"}).

The aforementioned data demonstrated that both HSCARG and USP7 inhibit NEMO polyubiquitination, and suppression of NEMO polyubiquitination by HSCARG is dependent on USP7. Next, we investigated whether HSCARG had a critical role in regulating the deubiquitination activity of USP7. The deubiquitination activity of USP7 was impaired in cells when HSCARG was knocked out ([Figure 4c](#fig4){ref-type="fig"}). Co-IP assay further confirmed that overexpression of USP7 had a weak effect on NEMO ubiquitination in *HSCARG*^*−/−*^ cells ([Figure 4d](#fig4){ref-type="fig"}). All these data indicate that HSCARG and USP7 function in concert in inhibiting NEMO polyubiquination, and HSCARG is important for the deubiquitination activity of USP7.

USP7 inhibits TNF*α*-induced NF-κB activation. Inhibition of NEMO polyubiquitination by USP7 suggested that USP7 probably inhibited cytokine-induced NF-*κ*B activation. We hence examined the effects of USP7 on I*κ*B*α* phosphorylation, p65 cytoplasm--nuclear translocation and NF-*κ*B transcriptional activity in TNF*α*-treated cells ([Figure 5](#fig5){ref-type="fig"}). Compared with control cells, knockout of USP7 in HCT116 cells stimulated the degradation of I*κ*B*α*, while overexpression of USP7 in 293T cells completely abolished the degradation of I*κ*B*α*. These observations were consistent with the changes of I*κ*B*α* phosphorylation ([Figure 5a](#fig5){ref-type="fig"}). We also found that overexpression of USP7 strongly suppressed translocation of p65 from the cytoplasm into the nucleus ([Figure 5b](#fig5){ref-type="fig"}). An NF-*κ*B luciferase reporter assay was carried out to analyze the effect of USP7 on NF-*κ*B transcriptional activity. The result showed that USP7 suppressed TNF*α*-induced NF-*κ*B transcription activity in a dose-dependent manner ([Figure 5c](#fig5){ref-type="fig"}). We further confirmed the regulatory role of HSCARG on USP7 activity by examining the influence of USP7 on IkB*α* degradation in *HSCARG*^*−/−*^ cells. The results showed that knockout of HSCARG attenuated the blocking effect of USP7 and promoted the degradation of IkB*α* ([Figure 5d](#fig5){ref-type="fig"}). IL-8 is a reported target of NF-*κ*B.^[@bib33]^ We also assessed the effect of USP7 on TNF*α*-induced IL-8 activation, and the result showed that USP7 strongly suppressed the activation of IL-8 ([Figure 5e](#fig5){ref-type="fig"}). Taken together, these data indicate that USP7 inhibits TNF*α*-induced NF-*κ*B activation and functions together with HSCARG in negatively regulating TNF*α*-stimulated NF-*κ*B signaling pathway.

Discussion
==========

The NF-*κ*B signaling pathway responds to various stimuli, such as cytokines, and oxidative and genotoxic stresses, which results in transcription of hundreds of genes. Both activation and termination of NF-*κ*B activity are strictly modulated at certain steps. In comparison to the many reported NF-*κ*B activators, fewer suppressors have been identified. HSCARG is a newly identified NF-*κ*B inhibitor.^[@bib32]^ Here we elucidated the detailed mechanism in which HSCARG inhibits NF-*κ*B activity. HSCARG interacts with USP7 and inhibits the polyubiquitination of NEMO, which decreases proteasomal degradation of I*κ*B*α* and further inhibits NF-*κ*B activity ([Figure 6](#fig6){ref-type="fig"}). We also characterized the inhibitory function of USP7 in the TNF*α*-activated NF-*κ*B signal pathway.

Protein ubiquitination has important functions in positive and negative regulation of the NF-*κ*B signaling pathway.^[@bib9]^ Polyubiquitination of NEMO is essential for IKK activation that is required for activation of NF-*κ*B.^[@bib21],\ [@bib34],\ [@bib35]^ In addition to K63-linked ubiquitin conjugation, NEMO is conjugated with linear ubiquitin chains by the linear ubiquitin chain assembly complex, which is also involved in TNF*α*-induced NF-*κ*B activation.^[@bib36],\ [@bib37]^ In this study, we demonstrated the suppression role of HSCARG on the ubiquitin conjugation of NEMO, indicating that HSCARG negatively regulates NF-*κ*B signaling via inhibition of NEMO polyubiquitination. To further elucidate the detailed molecular mechanism in which HSCARG inhibits NEMO ubiquitination, we examined the interaction between HSCARG and several DUBs, including A20, CYLD and USP7, to evaluate whether HSCARG suppresses NEMO ubiquitination by interacting with some DUBs. We found that HSCARG interacts with USP7, and inhibition of NEMO polyubiquitination and NF-*κ*B activity by HSCARG relies on the deubiquitination activity of USP7.

In our previous study, we demonstrated that HSCARG interacts with IKK*β* and suppresses its phosphorylation by promoting the interaction between PP2A and IKK*β*,^[@bib32]^ which provided one of the possible mechanisms to explain how HSCARG inhibits IKK*β* phosphorylation and NF-*κ*B activity. To further investigate which protein was the direct interaction partner of HSCARG, we carried out *in vitro* pull-down assays between HSCARG and NEMO or IKK*β*. Our result showed that NEMO, but not IKK*β*, was the direct interaction partner of HSCARG ([Supplementary Figure S2a](#sup1){ref-type="supplementary-material"}). Next, we examined whether IKK*β* affected NEMO--HSCARG interaction. The result showed that knockdown of IKK*β* by siRNA did not affect the binding between HSCARG and NEMO ([Supplementary Figure S2b](#sup1){ref-type="supplementary-material"}). These results indicate that HSCARG is likely to directly interact with NEMO and inhibit NEMO ubiquitination, which further affect IKK*β* phosphorylation. With regard to the observation that HSCARG regulates NF-*κ*B activity by affecting the degradation of RelA,^[@bib38]^ it occurs in the nucleus, indicating a spatiotemporal regulatory effect of HSCARG on NF-*κ*B activation. All together, these data indicate that HSCARG regulates NF-*κ*B pathway through different mechanisms.

USP7 has been found to participate in virus-mediated ubiquitination pathways. It has been reported that ICP0, a herpes simplex virus (HSV)-encoded protein, downregulates NEMO ubiquitination by interacting with USP7, and subsequently terminates Toll-like receptor-mediated NF-*κ*B activation induced by HSV infection.^[@bib39]^ USP7 also deubiquitinates RNA transcriptional activator-associated ubiquitin ligase and prevents it from self-ubiquitination-mediated degradation.^[@bib40]^ Recently, USP7 was reported to regulate NF-*κ*B transcription activity in the nucleus.^[@bib41]^ Here we demonstrated the suppressive role of USP7 in the TNF*α*-activated NF-*κ*B signaling pathway. Our results indicate that, in addition to virus-stimulated immunity, USP7 also regulates cytokine-triggered inflammatory reactions. Our findings present an important downregulatory mechanism of NF-*κ*B in addition to A20 and CYLD.

Our study also uncovered the critical role of HSCARG in regulating USP7 activity. Inhibition of NEMO ubiquitination by HSCARG is dependent on USP7 ([Figure 3c](#fig3){ref-type="fig"}), and the deconjugation ability of USP7 is limited when HSCARG is knocked out or knocked down ([Figures 4c and d](#fig4){ref-type="fig"}). We demonstrated that HSCARG and USP7 function cooperatively in suppression of NEMO ubiquitination. These observations indicate that both HSCARG and USP7 are essential in downregulation of NEMO ubiquitination. USP7 functions as a negative regulator of IKK activation by deubiquitination, and HSCARG is a key adaptor protein that functions in a coordinate manner.

It has been reported that certain viruses inhibit NF-*κ*B activity by recruitment of DUBs to escape destruction by host cells.^[@bib39]^ Because HSCARG inhibits NF-*κ*B activity by interacting with USP7, we hypothesize that HSCARG may function in virus-induced immunoreactions, which needs further investigation.

In summary, we demonstrate that HSCARG interacts with NEMO and suppresses polyubiquitination of NEMO by interacting with USP7, which further elucidate the detailed mechanism of how HSCARG inhibits NF-*κ*B activity. As overactivation of NF-*κ*B leads to persistent inflammation and immunoreactions that may cause damage and tumorigenesis, the important role of HSCARG in balancing NF-*κ*B activation suggests that it is a potential target for treating inflammatory diseases and cancer.

Materials and Methods
=====================

Antibodies and plasmids
-----------------------

Mouse anti-Myc (M47-3), anti-*α*-tubulin M175-3), anti-His (D291-3) and rabbit anti-*β*-actin were purchased from MBL (Nagoya, Japan); mouse anti-Flag (F3165) and anti-HA (H9658) from Sigma (St. Louis, MO, USA); and rabbit anti-I*κ*B*α* (No.9242), anti-p-I*κ*B*α* (No.2859), anti-p65 (No.4764), anti-USP7 (No.4833) and anti-NEMO (No.2685) from Cell Signaling Technology (Beverly, MA, USA). Recombinant TNF*α* and IL-1 were from PeproTech (Rocky Hill, NJ, USA). HSCARG was cloned into expression vectors pRK-HA, pRK-Flag and pcDNA-Myc-His, respectively, and verified by DNA sequencing. NEMO were cloned into pRK-HA or pRK-Flag expression vector. The shRNA plasmids were constructed by Shanghai Genechem Corporation (Shanghai, China). siRNA of NEMO (sc-29363) and IKK*β* (sc-35644) were from Santa Cruz (Dallas, TX, USA). The sequences of the sense strand of USP7 shRNA was 5′-ACCCUUGGACAAUAUUCCU-3′ and 5′-AGUCGUUCAGUCGUCGUAU-3′.

Cell culture and plasmid transfection
-------------------------------------

HEK 293T and HCT116 cells were cultured in Iscove\'s Modified Dulbecco\'s Medium (Invitrogen, Carlsbad, CA, USA) with 10% fetal calf serum (HyClone, Logan, UT, USA) at 37 °C in 5% CO~2~. Plasmids were transfected using MegaTran 1.0 transfection reagent following the manufacturer\'s instructions (Origene, Rockville, MD, USA).

Construction of HSCARG stable HEK 293T cell line
------------------------------------------------

Recombinant retroviruses expressing Flag-HA-tagged HSCARG and interleukin-2 receptor (IL-2R) *α* was constructed and transduced into HEK 293T cells. The positive cells expressing ectopic HSCARG were sorted by anti-IL-2R monoclonal antibody (13-0259, eBioscience, San Diego, CA, USA) conjugated with magnetic beads (MACS), and the expression of HSCARG were further confirmed by western blotting using anti-Flag/HA antibodies.

Co-IP assay
-----------

Cells were harvested and lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% NP-40, pH 7.4, 1 *μ*g/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 1 *μ*g/ml leupeptin and 1 *μ*g/ml pepstatin). The whole-cell lysate was precleaned by incubating with 70 *μ*l protein G sepharose beads (GE Healthcare, Milwaukee, MI, USA) at 4 °C for 1 h. Antibodies (5 *μ*g) or control IgG were added to 1 ml precleaned cell lysate for each reaction, and the sample was rotated overnight at 4 °C. Then, protein G sepharose beads were added and incubated for another 3 h. The sepharose beads were pelleted by centrifugation at 800 × *g* for 5 min and then washed three times with RIPA buffer. Precipitated proteins were fractionated by 12% SDS-PAGE and then transferred onto a nitrocellulose membrane (GE Healthcare). Membranes were probed with the indicated primary antibody for 2 h at room temperature, followed by the secondary antibody, and then detected using an Odyssey Infrared Imaging System and the software Odyssey V3.0 (LI-COR Biosciences, Lincoln, NE, USA).

His-ubiquitin pull-down assay
-----------------------------

Cells were first transfected with a His-ubiquitin plasmid and other plasmids as indicated. At 48 h posttransfection, cells were harvested and washed once with phosphate-buffered saline. For each reaction (1 × 10^6^ cells), 6 ml cell lysis buffer (6 M guanidinium chloride, 0.1 M Na2HPO4/ NaH2PO4, 10 mM Tris-HCl, pH 8.0) was added, followed by incubation for 30 min at room temperature. Ni2+--nitrilotriacetate-agarose beads (75 *μ*l) were added and incubated for another 4 h. The beads were collected by centrifugation at 2000 × *g* for 5 min and then sequentially washed with cell lysis buffers, buffer A (8 M urea, 0.1 M Na2HPO4/ NaH2PO4, 10 mM Tris-HCl, pH 8.0), buffer B (8 M urea, 0.1 M Na2HPO4/ NaH2PO4, 10 mM Tris-HCl, pH 6.3) and buffer C (8 M urea, 0.1 M Na2HPO4/ NaH2PO4, 10 mM Tris-HCl, 0.1% Triton X-100, pH 8.0). Finally, the beads were mixed with 50 *μ*l elution buffer containing 0.2 M imidazole, 5% SDS, 0.15 M Tris-HCl, 10% glycerol, pH 6.7 and boiled in SDS loading buffer. Fifteen microliters of each sample was loaded onto a 12% SDS-PAGE gel and analyzed by immunoblotting.

Luciferase reporter assay
-------------------------

HEK 293T cells were cultured in 24-well plates at 2 × 10^4^ cells per well. After 24 h, cells were transfected with a 1-*μ*g plasmid mixture. pRL-CMV (5 ng) was cotransfected as a control. After 16 h, cells were treated with TNF*α* (10 ng/ml) for 6 h, and then luciferase activity was assessed with a dual luciferase reporter assay kit according to the manufacturer\'s instructions (Promega, Madison, WI, USA). Each assay was performed in triplicate for at least three independent experiments.

Nuclear and cytoplasmic extract assay
-------------------------------------

HEK 293T or HCT116 cells were cultured in 6-cm dishes and harvested at 48 h. Nuclear and cytoplasmic extracts were prepared using Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, Waltham, MA, USA). Extracts were then fractioned by SDS-PAGE and analyzed by immunoblotting. LaminB and *α*-tubulin were used as nuclear and cytoplasmic loading controls, respectively.

Quantitative real-time PCR
--------------------------

RNAs were extracted using TRIzon reagent (CWBIO, Beijing, China) according to the manufacturer\'s instructions. The cDNAs were synthesized with FastQuant RT Kit (TIANGEN, Beijing, China), and qPCR were performed in Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA) using the SYBR Green Supermix (Bio-Rad). The primers used are as follows:

GAPDH forward primer: 5′-AACGGATTTGGTCGTATTGGG-3′

GAPDH reverse primer: 5′-TCGCTCCTGGAAGATGGTGAT-3′

IL-8 forward primer: 5′-CGGAAGGAACCATCTCACTGTG-3′ and

IL-8 reverse primer: 5′-AGAAATCAGGAAGGCTGCCAAG-3′.
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![HSCARG is a suppressor of NF-*κ*B signaling. (**a**) Immunoblot analysis of HSCARG expression in *HSCARG*^*−/−*^ cells (left panel) and HSCARG-stable cells (right panel). (**b**) Knockout of HSCARG promotes degradation of I*κ*B*α* (upper panel) while stable expression of HSCARG inhibits degradation of I*κ*B*α* (lower panel). Cells were treated with TNF*α* (10 ng/ml) for the indicated time, and then immunoblotting was performed using antibodies against I*κ*B*α*. Actin was used as a loading control. (**c**) Knockout of HSCARG results in nuclear accumulation of p65 stimulated by TNF*α*. Cells were treated with TNF*α* (10 ng/ml) for the indicated time, and then nuclear and cytoplasmic extracts were prepared. The distribution of endogenously expressed p65 was analyzed by immunoblotting using an anti-p65 antibody. Lamin B and α-tubulin were used as nuclear and cytoplasmic controls, respectively](cddis2014197f1){#fig1}

![HSCARG inhibits ubiquitination of NEMO. (**a**) HSCARG was coimmunoprecipitated with NEMO. HEK 293T cells were transfected with the indicated plasmids. At 48 h after transfection, cells were lysed and immunoprecipitated with anti-Flag antibody and then analyzed by immonoblotting with the indicated antibodies (left). The endogenous interaction between HSCARG and NEMO was examined by co-IP using anti-HSCARG antibody (middle). The effect of TNF*α* treatment on the HSCARG--NEMO interaction was assessed by co-IP as well (right). (**b**--**d**) HSCARG suppresses endogenous polyubiquitination of NEMO. HEK 293T cells were transfected with the indicated plasmids (**b** and **c**). Endogenous ubiquitin-conjugated NEMO was enriched and analyzed by His-ubiquitin pull-down assays. Polyubiquitination of NEMO was also examined in *HSCARG*^−/−^ cells (**d**)](cddis2014197f2){#fig2}

![HSCARG interacts with USP7, and inhibition of NEMO ubiquitination by HSCARG relies on the deubiquitination activity of USP7. (**a**) HSCARG interacts with USP7. Co-IP assays were performed to examine the interaction between HSCARG and USP7, CYLD or A20. HEK 293T cells were transfected with the indicated expression plasmids, and then whole-cell lysates were immunoprecipitated with anti-HA or anti-Flag antibodies, followed by immunoblotting with anti-Flag or anti-HA antibodies. WCL: 5% of whole-cell lysates. (**b**) Interaction between endogenous HSCARG and USP7 after TNF*α* treatment. HEK293T cells were treated with or without TNF*α* (5 ng/ml) for the indicated time, and then the endogenous interaction between HSCARG and USP7 was examined by co-IP analysis using anti-USP7 antibody. (**c**) NEMO is essential for the interaction of HSCARG with USP7. HEK 293T cells were transfected with control siRNA and NEMO siRNA (30 nM) for 72 h, and then treated with or without TNF*α* (5 ng/ml) for 20 min. The HSCARG--USP7 interaction was examined by co-IP using anti-USP7 antibody. (**d**) Inhibition of NEMO polyubiquitination by HSCARG is attenuated when USP7 is knocked down. HEK 293T cells were transfected with the indicated plasmids, and ubiquitin-conjugated NEMO was analyzed using His-ubiquitin pull-down assay](cddis2014197f3){#fig3}

![USP7 interacts with NEMO and inhibits NEMO polyubiquitination, and HSCARG is important for the deubiquitination activity of USP7. (**a**) Co-IP assay was performed to investigate the interaction between USP7 and NEMO. HEK 293T cells were transfected with the indicated plasmids. At 48 h after transfection, cells were harvested and lysed, and the whole supernatant was immunoprecipitated with relevant antibodies and then analyzed by immunoblotting. (**b**) The interaction among USP7, HSCARG and NEMO was confirmed by co-IP assay. HEK 293T cells transfected with the indicated plasmids were lysed 48 h after transfection, and proteins were immunoprecipitated with the indicated antibody followed by immunoblotting (left). The interaction of NEMO with USP7 was examined in *HSCARG*^*−/−*^ cells (middle). The effect of TNF*α* treatment on endogenous interaction among HSCARG, USP7 and NEMO was assessed by co-IP (right). (**c**) USP7 deubiquitinates NEMO. The wild-type and *HSCARG*^−/−^ HEK 293T cells were transfected with the indicated plasmids, and His-ubiquitin pull-down assay was performed to assess the level of NEMO ubiquitination. (**d**) HSCARG regulates deubiquitination activity of USP7. Co-IP assay was performed in both HSCARG wild-type and *HSCARG*^*−/−*^ HCT116 cells to examine the effect of USP7 on the level of ubiquitinated NEMO](cddis2014197f4){#fig4}

![USP7 inhibits TNF*α*-induced NF-*κ*B activation. (**a**) USP7 suppresses phosphorylation and degradation of I*κ*B*α*. Wild-type and *USP7*^*−/−*^ HCT116 cells were treated with TNF*α* (10 ng/ml) (left). 293T cells were transfected with the Flag-USP7 plasmid or empty vector and then stimulated by TNF*α* (10 ng/ml) for the indicated times (right). Then, cells were lysed and analyzed directly by immunoblotting using anti-p-I*κ*B*α* and anti-I*κ*B*α* antibodies. Actin was used as a loading control. (**b**) USP7 suppresses translocation of p65 from cytoplasm to nucleus. HEK 293T cells were transfected with Flag-USP7 or empty plasmids, and then nuclear and cytoplasmic extracts were prepared and analyzed. (**c**) USP7 inhibits the TNF*α*-induced NF-*κ*B activation. HEK 293T cells were co-transfected with various amounts of USP7 plasmid and an NF-*κ*B luciferase reporter plasmid. At 16 h posttransfection, cells were stimulated with or without TNF*α* for 6 h, and then reporter activity was measured (left). Western blotting was performed to confirm the expression of USP7 (right). (**d**) Knockout of HSCARG impairs the blocking effect of USP7 on I*κ*B*α* degradation. *HSCARG*^*−/−*^ cells and HEK 293T cells transfected with Flag-USP7 were treated with TNF*α* for different time and harvested at 48 h after transfection. The amounts of I*κ*B*α* were examined by immunoblot assay. (**e**) USP7 suppresses IL-8 transcription. HeLa cells were transfected with empty vector or Flag-USP7 and treated with or without TNF*α* for 48 h. The mRNA of IL-8 was evaluated by RT-qPCR analysis](cddis2014197f5){#fig5}

![Model of HSCARG and USP7 in regulation of TNF*α*-induced NF-κB activation. Both HSCARG and USP7 interact with NEMO and inhibit polyubiquitination of NEMO. Reduced NEMO polyubiquitination decreases proteasomal degradation of I*κ*B*α*, which retains NF-*κ*B in the cytoplasm and further suppresses NF-*κ*B activity](cddis2014197f6){#fig6}
